Immutep released encouraging Phase 2 survival data from EFTISARC-NEO trial showing 81.1% 12-month disease-free survival and 94.1% local recurrence-free survival in 38 soft tissue sarcoma patients receiving efti + KEYTRUDA + radiotherapy. The company expanded its U.S. patent portfolio with a key patent for efti-based combination therapies valid through 2038. Additional late-breaking data from ACR Convergence 2026 demonstrated statistically significant, exposure-dependent inhibition of T-cell-driven immune responses with IMP761 in healthy volunteers. These clinical and intellectual property developments support advancement of Immutep's immuno-oncology pipeline.
| Date (UTC) | Headline | Source |
|---|---|---|
| Nov 18, 2026 | Immutep Reports Encouraging Survival Data From Phase 2 Cancer Trial | Benzinga |
| Nov 11, 2026 | Immutep Further Expands United States Patent Estate for Efti-Based Combination Therapies | Yahoo |
| Nov 10, 2026 | EFTISARC-NEO Phase II Sarcoma Survival Data: Efti + KEYTRUDA + Radiotherapy Shows 81.1% 12-Month DFS, 94.1% LRFS And 86.2% DMFS | Benzinga |
| Nov 7, 2026 | IMP761 Late-Breaking Abstract at ACR Convergence 2026 Highlights Statistically Significant T-Cell Inhibition | Yahoo |
| Nov 5, 2026 | Immutep Announces Upcoming Poster Presentations at CTOS 2026 and ESMO Immuno-Oncology Congress | Yahoo |
Compliance Note: This summary is for informational purposes only and reflects publicly disclosed material published during the specified reporting window. LIVE_DATA as of 2026-11-19T01:08:48Z. No investment recommendation is expressed or implied. Readers should conduct independent due diligence and consult with qualified advisors.
Critical Data Gap: Earnings dates, historical EPS actuals, consensus estimates, and guidance are not disclosed in available data. Latest EPS (trailing) is –$0.0539 AUD, indicating the company is unprofitable.
| Metric | Value | Assessment |
|---|---|---|
| Trailing EPS | –$0.0539 | Loss-making |
| EPS Growth YoY | Not disclosed | Coverage constrained |
| Revenue Growth YoY | 24,185% (*)† | Extreme anomaly—likely restart or accounting event |
| Forward P/E | Not disclosed | N/A (unprofitable) |
| Guidance | Not available | No forward outlook disclosed |
* The 24,185% revenue growth figure is anomalous and likely reflects a corporate restructuring, significant deal, or data anomaly rather than organic operational momentum. Requires clarification from company disclosures.
Data Status: Financial statements (income statement, cash flow) not available in live data.
| Metric | Value | Implication |
|---|---|---|
| Gross Margin | Not disclosed | Visibility limited |
| Operating Margin | Not disclosed | Visibility limited |
| Net Margin | Negative (EPS –$0.0539) | Unprofitable |
| ROE / ROIC | Not disclosed | Likely negative—unsuitable metric for loss-making firm |
| FCF TTM | Not disclosed | Visibility limited |
| Quality Flags | Hyper-growth (flagged) No strong profitability (flagged) |
Company is in R&D/pre-revenue or early-stage biotech phase |
Data Status: Balance sheet and cash flow statements not available in live data.
| Metric | Value | Assessment |
|---|---|---|
| Cash & Equivalents | Not disclosed | Critical gap for burn-rate analysis |
| Total Debt | Not disclosed | Critical gap |
| Net Debt / EBITDA | Not disclosed | Not meaningful (negative EBITDA) |
| Interest Coverage | Not disclosed | Not meaningful (unprofitable) |
| Current Ratio | Not disclosed | Liquidity unknown |
| Share Dilution | Not disclosed | Dilution history unknown |
| Weak Balance Flag | NOT flagged | System shows "false," but lack of visibility is concerning for biotech |
| Metric | Value | Interpretation |
|---|---|---|
| Trailing P/E | Not meaningful (EPS negative) | Company loss-making; P/E not applicable |
| Forward P/E | Not disclosed | No consensus forward earnings |
| PEG Ratio | Not calculable | Requires forward EPS growth—not available |
| Price / Sales | Not calculable (Revenue TTM not disclosed) | Market cap $35.4M; Revenue coverage constrained |
| Price / FCF | Not meaningful (FCF not disclosed; likely negative) | Unprofitable; free cash flow typically negative in pre-commercial biotech |
| EV / EBITDA | Not meaningful (negative EBITDA) | Company loss-making |
| Sector Context | Biotech peer median not disclosed | Relative valuation analysis not possible |
| Market Cap | $35.4M AUD (~$23M USD) | Micro-cap; illiquid; speculative risk profile |
Data Status: Wall Street analyst coverage and targets not available in live data.
| Metric | Value | Comment |
|---|---|---|
| Consensus Rating | Not disclosed | No analyst consensus available |
| Price Target (Mean) | Not disclosed | No data |
| Price Target (High/Low) | Not disclosed | No data |
| Implied Upside | Cannot calculate | No target available |
| Analyst Dispersion | Unknown | Coverage likely sparse for micro-cap ASX stock |
| Risk Factor | Status | Severity |
|---|---|---|
| Institutional Ownership | Not disclosed | Unknown |
| Insider Activity | Not disclosed | Unknown |
| Short Interest | Not disclosed | Unknown |
| Liquidity | Micro-cap; avg volume 8.87M shares | HIGH RISK |
| Volatility (Beta) | 2.03 (highly volatile) | HIGH RISK |
| 52-Week Price Action | –91.8% YTD; down from $0.47 to $3.25 current; 52W low $0.02 | SEVERE |
| Financial Distress | Unprofitable; no visibility on cash position | CRITICAL |
| Sector Risk | Early-stage biotech; clinical/pipeline risk; regulatory risk | HIGH RISK |
- Unprofitable Pre-Commercial Biotech: Immutep is a loss-making, early-stage immunotherapy developer with negative EPS (–$0.0539) and no disclosed earnings visibility or guidance. Traditional valuation metrics do not apply.
- Critical Data Gaps: Financial statements, cash position, debt levels, clinical trial status, and analyst coverage are not available. This severely limits the ability to assess survival probability or clinical value.
- Extreme Volatility & Micro-Cap Illiquidity: Beta 2.03; 52-week loss of –91.8%; market cap $35.4M. High risk of further dilution or capital distress. Not suitable for conservative investors.
- Pipeline-Dependent Valuation: Stock price is 100% dependent on clinical milestone announcements, partnerships, or capital raises. No intrinsic earnings power. Requires deep biotech expertise and high risk tolerance.
- Recommendation: AVOID for institutional portfolios. Only for venture/biotech specialists with dedicated pipeline research and high-risk capital allocation. Obtain latest quarterly financials, cash burn analysis, and clinical trial updates directly from company before any position consideration.
IMMP Stock Analysis & Forecast
Is IMMP a Good Investment in 2026?
Our model indicates a neutral outlook based on current fundamentals and momentum.
IMMP Stock Forecast
Based on recent earnings trends, valuation metrics, and sector performance, IMMP shows balanced risk-reward characteristics.
Should You Buy IMMP Now?
Investors should consider market conditions, volatility, and long-term positioning before taking a position in IMMP.